An Open-label Extension Study of Ivacaftor in Children With CF and a CFTR Gating Mutation Initiating Treatment at Age 2-5 Years (KLIMB)

BACKGROUND: KIWI (NCT01705145) was a 24-week, single-arm, pharmacokinetics, safety, and efficacy study of ivacaftor in children aged 2 to 5 years with cystic fibrosis (CF) and a CFTR gating mutation. Here, we report the results of KLIMB (NCT01946412), an 84-week, open-label extension of KIWI. METHOD...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cyst Fibros
Main Authors: Rosenfeld, Margaret, Cunningham, Steve, Harris, William T., Lapey, Allen, Regelmann, Warren E., Sawicki, Gregory S., Southern, Kevin W., Chilvers, Mark, Higgins, Mark, Tian, Simon, Cooke, Jon, Davies, Jane C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6821553/
https://ncbi.nlm.nih.gov/pubmed/31053538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcf.2019.03.009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados